Is Lack of Competition Raising Your Health Care Costs?

Is Lack of Competition Raising Your Health Care Costs?

The Herfindahl-Hirschman Index for commercial insurance markets has remained consistently above the 1,800-point threshold that federal regulators use to identify anticompetitive environments. This finding, highlighted in the American Medical Association’s 2025 analysis, underscores a persistent crisis in the health care economy where a staggering lack of competition among insurers continues to escalate. For twenty-five years, researchers have monitored how market consolidation influences both the financial burden on patients and the operational viability of independent medical practices. By evaluating hundreds of metropolitan areas across all 50 states, the study provides a critical diagnostic look at how dominant carriers shape the price and quality of care in the 2026 landscape. This research serves as a vital tool for federal regulators who monitor anticompetitive behavior that threatens the long-term affordability of the modern medical landscape while providing empirical evidence of insurance dominance.

Measuring Market Dominance

Tracking Concentration Levels

Economists and federal authorities rely on the Herfindahl-Hirschman Index as a mathematical standard for measuring market density and potential monopoly power. Under the 2023 merger guidelines established by the Department of Justice and the Federal Trade Commission, a market is classified as highly concentrated when its total index points exceed the 1,800-point mark. This specific threshold indicates that a handful of large players hold disproportionate power, which often leads to reduced innovation and higher costs for consumers. By applying these rigorous guidelines to enrollment data, the study reveals exactly where competition has stalled in metropolitan regions. These metrics offer a granular perspective on how individual insurers dominate specific geographic market segments, allowing regulators to pinpoint areas where the lack of options for both patients and providers is most severe. This statistical foundation is essential for identifying major antitrust risks.

The geographic distribution of these high concentration scores reveals that many regions are increasingly vulnerable to the unchecked influence of insurance giants. In the current 2026 landscape, the data highlights that nearly all metropolitan areas suffer from a lack of meaningful competition, creating an environment where a few dominant firms dictate the terms of engagement. For patients living in these areas, high concentration scores often correlate with higher premiums and fewer plan options. For health care providers, the presence of such massive carriers creates significant barriers to entry for smaller, competing insurance plans that might offer more favorable terms or innovative care models. The consistent nature of these high index scores suggests that the insurance market has become calcified, with the same major players maintaining their grip on local economies year after year. Understanding these geographic trends is the first step toward implementing effective policies.

Analyzing Long-Term Market Stagnation

The commercial insurance sector has remained stubbornly concentrated for over a decade, with data showing that 95% of metropolitan markets currently lack healthy competition. This stagnation is not a temporary trend but a systemic reality where, in 90% of metropolitan areas, at least one insurer maintains a market share of 30% or higher. More concerning is the fact that in nearly half of these regions, a single carrier controls more than 50% of the market share, leaving little room for new entrants to gain a foothold. This level of dominance allows established regional players to exert significant control over price points and network access. While federal regulators have attempted to introduce more oversight, the sheer scale of these insurance conglomerates makes it difficult for traditional market forces to correct themselves. The result is a commercial landscape where the lack of diversity in plan options contributes to rising costs.

While the introduction of Affordable Care Act exchanges briefly appeared to introduce new local options, this expansion often masked a more troubling surge in concentration within the broader market. When exchange data is isolated, the underlying employer-sponsored and private segments show a significant increase in concentration levels, further entrenching the power of entities like Blue Cross Blue Shield. Simultaneously, the Medicare Advantage landscape has experienced a troubling reversal of previous competitive trends. For the first time in nearly a decade, market concentration in these private Medicare plans has increased, driven largely by the expansion of national corporations. UnitedHealth Group and other major providers now dominate the vast majority of metropolitan areas, suggesting that even as more seniors enroll in these plans, their actual choice of providers is shrinking. This dual concentration across both commercial and senior markets indicates a pervasive lack of competition.

Consequences of Insurer Power

Understanding Monopsony and Physician Leverage

When a single insurer dominates a specific region, it creates a “monopsony,” a market condition where one buyer holds excessive power over many sellers. In the health care context, this means that insurance companies have an overwhelming advantage when negotiating with physicians and medical facilities. For independent medical practices, this imbalance makes it nearly impossible to negotiate fair contracts or walk away from unfavorable terms that may compromise care quality. Since approximately 47% of physicians continue to work in small groups of ten or fewer clinicians, they lack the administrative resources and scale to challenge multi-billion-dollar insurance conglomerates effectively. This downward pressure on payments forces many practices to see more patients in less time, which can ultimately lead to reduced access to care and a decline in service quality for the general public. Doctors are often forced to accept terms just to remain viable.

The power imbalance caused by insurer dominance is further exacerbated by the rise of vertical integration, a strategy used to expand control following blocked horizontal mergers. Insurance giants have shifted their focus toward acquiring pharmacy benefit managers and direct physician groups, creating “closed-loop” systems. In these arrangements, the insurer also acts as the employer of the doctor and the manager of the pharmacy benefits, which naturally disadvantages independent providers. These vertical structures often evade traditional antitrust scrutiny because they do not technically merge two competing insurers, yet they can be equally damaging to market competition. By owning various links in the health care delivery chain, dominant carriers can steer patients toward their own providers and pharmacies, making it difficult for independent practices to survive. This trend suggests that the lack of competition is not just about market share, but about total control of the patient journey.

Balancing Competing Economic Arguments

While the evidence of insurer dominance is compelling, representatives of the insurance industry argue that the primary drivers of rising health care costs are actually hospital consolidations and large physician groups. They contend that their massive scale is a necessary defensive measure to negotiate lower rates with these expanding provider systems, which theoretically benefits consumers through lower premiums. From this perspective, the concentration of insurance power is seen as a tool for cost containment rather than a cause of inflation. However, the critical question remains whether these negotiated savings are truly passed on to patients or if they primarily serve to bolster corporate profit margins. Regulators must carefully evaluate these competing economic arguments to determine if the lack of competition is suppressing innovation or if it is a byproduct of a broader trend toward consolidation across the entire medical sector. Balancing these perspectives requires a deep look.

To address the challenges identified in the 2026 landscape, federal regulators focused on expanding the scope of antitrust enforcement to include vertical integration and regional monopsonies. Legislators began exploring policies that increased transparency in pharmacy benefit management and protected the autonomy of independent medical practices from corporate takeovers. These actions aimed to rebalance the power dynamics between massive insurance conglomerates and individual health care providers. By prioritizing competitive health insurance markets, the government sought to ensure that patients regained access to a wider variety of affordable care options. Moving forward, the emphasis shifted toward fostering an environment where innovation and quality, rather than market dominance, dictated the success of insurance carriers. Ultimately, the sustainability of the health care system required a commitment to dismantling entrenched monopolies and ensuring that financial savings directly benefited individuals.

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later